Muscarinic Antagonists: Pharmacology and Clinical Applications

Atropine is a competitive antagonist at all five muscarinic receptor subtypes, making it the broadest-acting muscarinic blocker in clinical use. Because it is a tertiary amine, atropine is un-ionized at physiological pH, crosses the blood-brain barrier readily, and is absorbed after oral and intramuscular administration. This lack of receptor subtype selectivity means that atropine blocks muscarinic receptors in the heart, smooth muscle, exocrine glands, and central nervous system simultaneously, producing a full anticholinergic picture at higher doses.

The primary clinical indications for atropine follow directly from its mechanism. In the heart, vagal tone slows the sinoatrial node by activating muscarinic subtype 2 receptors; atropine blocks this vagal slowing and is used as the first-line treatment for symptomatic bradycardia and atrioventricular block. In toxicology, atropine is the antidote for organophosphate and carbamate poisoning, where it is given in large, rapidly escalating doses to counteract the life-threatening accumulation of acetylcholine — this indication was covered in depth in Module 3. In ophthalmology, topical atropine produces prolonged pupil dilation and paralysis of accommodation by blocking muscarinic subtype 3 receptors in the iris sphincter and ciliary muscle; the duration of effect from a single drop can last one to two weeks. Preoperatively, atropine reduces airway secretions and prevents reflex bradycardia during surgical airway manipulation.

Scopolamine shares atropine's tertiary amine structure and muscarinic receptor targets, but has a slightly different ring structure that produces greater central nervous system penetration and a distinct clinical profile. At doses that produce modest peripheral anticholinergic effects, scopolamine causes sedation, amnesia, and suppression of nausea, making it pharmacologically distinct from atropine despite acting at the same receptors.

The principal clinical use of scopolamine is prevention and treatment of motion sickness. It works by blocking muscarinic input to the vestibular nuclei in the brainstem and to the vomiting center, interrupting the signal that translates vestibular mismatch into nausea. The transdermal patch formulation delivers drug at a steady rate for up to three days, avoiding the peaks and troughs of oral dosing. Scopolamine produces more pronounced central nervous system adverse effects than atropine at equivalent doses, including confusion and hallucinations, which limits its use in elderly patients.

Ipratropium is atropine with its nitrogen atom quaternized — that is, converted from a tertiary to a quaternary amine by adding a chemical group that gives the nitrogen a permanent positive charge. This charge prevents the molecule from crossing lipid membranes, which has two clinically important consequences: ipratropium cannot penetrate the blood-brain barrier, and it is not meaningfully absorbed from the lung surface after inhalation. The result is a drug that produces local bronchodilation without central nervous system effects or systemic cardiovascular effects at inhaled doses.

In the airways, ipratropium blocks muscarinic receptors on bronchial smooth muscle and on mucus-secreting glands, producing bronchodilation and modest reduction in secretions. In chronic obstructive pulmonary disease, parasympathetic tone is a significant driver of baseline bronchoconstriction, and ipratropium is a first-line bronchodilator for this reason. In acute severe asthma, ipratropium is used as an adjunct to short-acting beta-2 agonists because the two mechanisms are complementary and additive; ipratropium is not used as monotherapy for asthma maintenance.

The onset of bronchodilation from ipratropium is slower than from short-acting beta-2 agonists — approximately 15 to 30 minutes versus 3 to 5 minutes — which explains why the two are used together in acute settings rather than ipratropium alone.

In the striatum, dopaminergic neurons projecting from the midbrain normally suppress cholinergic interneuron activity. This balance between dopaminergic inhibition and cholinergic excitation is essential for smooth motor coordination. In Parkinson disease, the progressive loss of these dopaminergic neurons removes the suppression of cholinergic interneurons, creating relative cholinergic overactivity in the striatum. This imbalance contributes to the tremor and rigidity components of the Parkinson disease motor syndrome.

Benztropine and trihexyphenidyl are tertiary amine muscarinic antagonists that cross the blood-brain barrier and reduce cholinergic interneuron activity in the striatum, partially restoring the dopaminergic-cholinergic balance. Their therapeutic effect is narrow and selective: they reduce tremor and rigidity but have no meaningful benefit for bradykinesia or postural instability, the features that most impair function in Parkinson disease. Because of this limited efficacy and significant cognitive adverse effect risk, benztropine and trihexyphenidyl have been largely replaced by levodopa and dopamine agonists as the first-line treatment for Parkinson disease. They are currently used as second-line agents for tremor control in younger patients with Parkinson disease when dopaminergic therapy is insufficient.

Current guidelines recommend against using these agents in patients older than approximately 70 years with Parkinson disease. The central anticholinergic adverse effects — confusion, memory impairment, hallucinations, and delirium — are poorly tolerated in this population and are clinically difficult to distinguish from the cognitive decline that accompanies Parkinson disease itself, making management much harder.

Dopamine receptor subtype 2 blocking drugs — including typical antipsychotics like haloperidol and antiemetics like metoclopramide — can produce drug-induced extrapyramidal symptoms by reducing dopaminergic tone in the striatum, recreating the cholinergic-dopaminergic imbalance of Parkinson disease. The most acute and distressing of these reactions is acute dystonia, characterized by involuntary sustained muscle contractions producing abnormal postures.

Benztropine given intramuscularly or intravenously is the first-line treatment for acute dystonic reactions, producing rapid resolution within 5 to 15 minutes of parenteral administration. Diphenhydramine, a first-generation antihistamine with substantial anticholinergic activity, is an acceptable alternative at 50 mg intramuscularly or intravenously.

For chronic drug-induced parkinsonism in patients continuing antipsychotic therapy, oral benztropine or trihexyphenidyl can be used, but the preferred strategies are to reduce the antipsychotic dose, switch to an atypical antipsychotic with lower dopamine receptor subtype 2 affinity, or switch to an agent like clozapine or quetiapine that has intrinsic muscarinic antagonist activity — these agents rarely cause extrapyramidal symptoms because their anticholinergic properties counterbalance their dopamine blockade.

Cumulative anticholinergic drug exposure is associated with cognitive impairment and increased dementia risk, particularly in older adults. The mechanism involves progressive blockade of muscarinic receptors in brain regions that mediate learning and memory, including the hippocampus and prefrontal cortex. This association has been documented in prospective cohort studies and is dose-dependent: greater total anticholinergic exposure over time correlates with greater cognitive risk.

A particularly important clinical interaction occurs when a patient with Alzheimer disease is taking an acetylcholinesterase inhibitor — a drug whose mechanism is to increase acetylcholine levels in the brain — and is simultaneously prescribed any drug with significant anticholinergic activity. The anticholinergic drug directly opposes the pharmacological mechanism of the acetylcholinesterase inhibitor, negating its intended benefit. This situation is more common than might be expected, because the same patient population that receives acetylcholinesterase inhibitors — older adults with multiple comorbidities — is also the population most likely to receive bladder antimuscarinics, first-generation antihistamines for sleep, and tricyclic antidepressants for pain or depression.

When initiating acetylcholinesterase inhibitor therapy in a patient with Alzheimer disease, a systematic review of all other medications for anticholinergic activity is part of appropriate prescribing. Agents with high anticholinergic burden should be deprescribed or substituted with alternatives carrying less anticholinergic activity, such as second-generation antihistamines for allergy management or mirabegron for overactive bladder.

Orthostatic hypotension is defined as a sustained drop in systolic blood pressure of at least 20 millimeters of mercury or diastolic blood pressure of at least 10 millimeters of mercury within three minutes of standing. Normally, standing causes gravitational blood pooling in the lower extremities, which is detected by baroreceptors in the carotid sinus and aorta; this triggers reflex sympathetic activation that increases heart rate and peripheral vascular resistance, restoring blood pressure and cerebral perfusion within seconds. Symptoms of orthostatic hypotension — lightheadedness, near-fainting, or fainting — arise when this compensatory reflex fails.

Neurogenic orthostatic hypotension occurs when the sympathetic nervous system pathway itself is damaged, most commonly in Parkinson disease with autonomic involvement, multiple system atrophy, and diabetic autonomic neuropathy. The key distinguishing feature of neurogenic orthostatic hypotension is the absence of compensatory tachycardia on standing — because the sympathetic pathway is damaged, the heart cannot accelerate to compensate for the blood pressure drop. In contrast, non-neurogenic orthostatic hypotension (from dehydration, medications, or cardiac pump failure) is accompanied by a compensatory increase in heart rate, because the sympathetic system is intact.

Non-pharmacological measures are always the starting point: compression stockings and abdominal binders reduce venous pooling; increased salt and fluid intake expands plasma volume; head-of-bed elevation at night reduces supine hypertension while improving morning blood pressure. These measures alone may be insufficient in severe neurogenic disease, at which point drug therapy is added.

Fludrocortisone is a synthetic mineralocorticoid that acts on the kidney to retain sodium and water, expanding plasma volume. It enhances the pressor response to standing by increasing the volume available for the heart to pump. Adverse effects reflect its mineralocorticoid mechanism and include supine hypertension, edema, and potassium loss.

Midodrine is a prodrug that is converted in peripheral tissues to an active alpha-1 adrenoceptor agonist. By constricting peripheral arterioles and veins, it raises blood pressure in the standing position. Midodrine does not cross the blood-brain barrier, so it has no central nervous system effects. Because it also constricts vessels in the supine position, it must not be taken within four to six hours of bedtime — supine hypertension during sleep is the main adverse effect to avoid.

Droxidopa is a synthetic amino acid that is converted directly to norepinephrine by a decarboxylase enzyme present throughout the body. It is particularly useful when sympathetic nerve terminals are still present but are unable to synthesize enough norepinephrine — a situation that occurs in some forms of Parkinson disease and in dopamine beta-hydroxylase deficiency. Unlike midodrine, which is a receptor agonist, droxidopa restores the neurotransmitter itself.

Postural orthostatic tachycardia syndrome is defined as a heart rate increase of 30 beats per minute or more within 10 minutes of standing, in the absence of orthostatic hypotension, accompanied by symptoms of orthostatic intolerance such as lightheadedness, palpitations, and fatigue. Unlike neurogenic orthostatic hypotension, blood pressure is maintained in postural orthostatic tachycardia syndrome, but the compensatory tachycardia is exaggerated beyond what is physiologically necessary.

The underlying mechanisms are heterogeneous and include relative hypovolemia, partial sympathetic denervation of the lower limbs producing pooling and reflex tachycardia, and impaired norepinephrine clearance. Non-pharmacological management — volume expansion with salt and fluid, compression garments, and graded exercise — is the foundation of treatment.

When pharmacological rate control is needed, low-dose propranolol is one of the most commonly used agents. Propranolol reduces heart rate by blocking cardiac beta-1 adrenoceptors, attenuating the exaggerated tachycardia. It must be used cautiously in patients with the hyperadrenergic subtype of postural orthostatic tachycardia syndrome, where elevated catecholamine levels are present — blocking peripheral beta-2 vasodilator receptors in this context can paradoxically worsen blood pressure. Ivabradine, which lowers heart rate through a different mechanism without affecting blood pressure, is used as an alternative when beta-blocker adverse effects are limiting.

Diabetic autonomic neuropathy is a common complication of long-standing diabetes that damages both sympathetic and parasympathetic fibers throughout the body. It is underdiagnosed because its manifestations are diverse and often attributed to other causes.

Cardiovascular manifestations include resting tachycardia (from loss of vagal tone to the sinoatrial node), exercise intolerance, and orthostatic hypotension from damage to sympathetic vasomotor fibers — treated with fludrocortisone and midodrine as described above. Silent myocardial ischemia is a serious consequence: because sympathetic pain fibers from the heart are damaged, patients with diabetic autonomic neuropathy may have coronary artery disease without chest pain, masking the diagnosis.

Gastrointestinal manifestations include gastroparesis — delayed gastric emptying from vagal efferent damage — producing early satiety, nausea, and erratic glycemic control after meals; and alternating constipation and diarrhea from colonic and small bowel dysmotility. Neurogenic bladder, presenting initially as reduced bladder sensation and large residual urine volumes, is a genitourinary consequence.

Management of diabetic autonomic neuropathy is primarily directed at optimizing glycemic control to slow progression, supplemented by symptom-specific pharmacotherapy for each organ system affected.